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ABSTRACT 
Objective: Nasal delivery provides a route of entry of drug to the brain that circumvents the obstacle for blood-brain barrier allowing direct drug 
delivery to the central nervous system via olfactory neurons. The objective of work was to prepare solid lipid nanoparticles of antimalarial drug 
artemether for brain delivery through olfactory delivery route for treatment of cerebral malaria. 
Methods: Artemether containing solid lipid nanoparticles were prepared with soya lecithin and poloxamer 407 with a hot homogenization method 
followed by solvent injection technique. The prepared solid lipid nanoparticles were characterized by their shape, particle size, zeta potential, 
encapsulation efficiency total drug content and drug release study. 
Results: These solid lipid nanoparticles were observed spherical in shape in scanning electron microscopy, the optimized size was found to be 
211.6 nm (Polydispersity Index PI<0.415), with −27mV zeta potential value. The maximum % yield of the formulation was found to be found 49%. 
The maximum entrapment efficiency was 82% (w/w), and optimized formulation showed 98.07±1.521% drug release form formulation. In vivo 
studied were conducted on wistar rats after administration of artemether containing solid lipid nanoparticles intranasally and compared with plain 
artemether solution administered orally. The results of optimized formulation showed the value of biological half-life (T1/2) was 4.95 h, maximum 
serum concentration Cmax was 644.60ng/ml, time for drug to reach peak plasma concentration Tmax was 1 h volume of distribution (Vd) was 2.7l/kg, 
body clearance (Cl) was 0.37 lh/kg and Area under curve [AUC]0∞ was 3970.5 nghr/ml for formulation. 
Conclusion: The results revealed that the brain: plasma concentration ratio was higher after intranasal administration of solid lipid nanoparticles 
(SLNs) of artemether than the oral route. In conclusion, the intranasal administration of lipid nanoparticles of artemether could provide complete 
protection against cerebral malaria. 
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Malaria is an infectious disease caused by the Plasmodium genus of a 
protozoan parasite. During the course of the disease, an initial 
asymptomatic infection of the liver is followed by parasites invasion 
into red blood cells, causing clinical symptoms of malaria. The most 
severe complication of Plasmodium falciparum infection is cerebral 
malaria, which implies the presence of neurological features, 
especially impaired consciousness. In cerebral malaria, 
sequestration of the parasitized erythrocytes in the brain 
microvasculature reduces the blood flow and triggers a severe 
immune pathological response [1, 2]. Existing treatments for malaria 
include a limited number of clinically effective antimalarial agents. 
The artemether is a potent and rapidly acting antimalarial agent 
which is enlisted in WHO List of Essential Medicines [3] for the 
treatment of severe multiresistant malaria. It is active against P. 
vivaxas well as chloroquine-sensitive and chloroquine-resistant 
strains of P. falciparum. It is also indicated in the treatment of 
cerebral malaria. Currently, artemether is available as tablets for 
oral therapy and as an intramuscular oily injection for the treatment 
of severe malarial infections. The oral bioavailability of artemether 
is low (∼40%) due to its poor aqueous solubility and degradation in 
stomach acids [4] whereas intramuscular injection suffers from 
disadvantages such as pain on injection and; slow and erratic 
absorption on intramuscular administration [5]. These shortcomings 
of therapy could be overcome by the development of navel carriers or 
by administration of a drug through alternative route like rectal or 
transdermal administration of antimalarials have been investigated 
[6,7]. On the other side drug delivery to the brain is made difficult due 
to the presence of blood-brain barrier (BBB), which is formed by tight 
junctions within the capillary endothelium of the vertebrate brain. 
Since cerebral malaria gets fetal within a few days of infection hence 
immediate treatment is necessary. Intranasal administration would 
offer a noninvasive alternative to traditional invasive intracerebro-
ventricular injection as a direct delivery of therapeutics to the central 
nervous system, effectively bypassing the blood-brain barrier (BBB). 
Recently intranasal drug delivery is recognized to be a useful and 
reliable alternative to oral and parenteral routes. The drug delivery 
into central nervous system through intranasal route has been 
reported [8-11] either in humans or animal models of Alzheimer’s 
disease [12, 13], brain tumours [14, 15], epilepsy [16], pain [17] and 
sleep disorders [18], in proposed work first time we tried to deliver 
drug to Central nerves system (CNS) in the treatment of cerebral 
malaria. The nanoparticulate system widely investigated because of 
many advantages such as controlled drug release pattern, drug 
targeting ability, and smaller size, improvement of therapeutic efficacy 
and reduction of toxicity. Recently the Jain el al.[2014] reported the 
optimization of the artemether loaded nanostructure lipid carriers for 
intranasal delivery [19]. In present work we tried to prepare solid 
lipid nanoparticles for intranasal delivery of the drug. These solid lipid 
nanoparticles would have great potential to deliver the drug to CNS 
and could show controlled drug release and site-specific drug 
targeting. These new delivery strategies could increase the uptake of 
artemether in the infected brain and could improve the patient 
compliance and therapeutic index of treatment therapy. 
MATERIALS AND METHODS 
Materials 
Artemether was procured as a gift sample from IPCA laboratory 
(India), Glyecerylmonosterate (GMS) was purchased from CDH 
(India). Lecithin was purchased from Across chemicals (India). 
Pluronic F127 was purchased from Himedia (India). All other 
reagents used in this study were of analytical grade. 
Preparation of solid lipid nanoparticles [20] 
Solid lipid nanoparticles containing artemether were prepared using the 
hot homogenization method. The aqueous phase was prepared by 
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dissolving the surfactant (lecithin) and co-surfactant (poloxamer 407) in 
50 ml of double distilled water. The organic solution was prepared by 
completely dissolving the artemether and lipid glyecerylmonosterate in 
5 ml of water-miscible solvent (methanol) in a water bath at 70 °C, which 
is above the melting point of the glyecerylmonosterate (GMS). The 
resultant organic solution was injected into 50 ml of an aqueous phase 
containing the surfactant, with mechanical stirring (Remi Instruments 
Ltd, India) at 1,000 rpm at 61 °C for 1 h. The nanosuspension formed 
was allowed to cool at room temperature. As the temperature drops 
under such conditions, the lipid droplets solidify producing small lipid 
nanoparticles. The prepared nanoparticles were purified by 
centrifugation at 15000 rpm for 10 min using ultracentrifuge 
(Optimamax-XP, Backman coulter (USA) freeze-dried (Wizard 2 
Advantage plus, VerTis USA) and stored in the refrigerator for further 
use. Various variables such as the lipid, surfactant and co-surfactant 
concentrations were considered during the optimization of the 
formulation (table 1). 
Characterization of solid lipid nanoparticles 
Surface morphology 
Surface morphology of solid lipid nanoparticles was confirmed by 
Scanning electron microscopy (JEOL JSM6390 A) with auto fine 
coater (JEOL1600). The sample was scanned at 5-15 Kv electron 
beam. SEM photograph of solid lipid nanoparticles is given in fig. 1. 
Size and size distribution 
The average particle sizes of the solid lipid nanoparticles dispersion 
were determined using particle size analyzer Zetasizer (Malvern 
Instruments, UK). The sample of dispersion was diluted to 1:9 v/v with 
double distilled water to ensure that the light scattering intensity was 
within the instrument’s sensitivity range (table 1). Polydispersity index 
which is a range of measurement of particle sizes within the measured 
sample was calculated as the weight average molecular weight divided 
by the number average molecular weight and given in table 1. 
Zeta potential  
Zeta potential value shows the electrokinetic potential of  colloidal 
systems. The significance of zeta potential is that its value can be 
related to the stability of colloidal nanoparticles. The zetapotential 
values of formulations are given in table 1. 
Yield of lipid nanoparticles 
The total amount of nanoparticles obtained were weighed 
individually for each batch and percentage yield was calculated 
taking into consideration the weight of drug and polymer by using 
the following formula and observations are shown in table 1. 
---------Eq 1 
Percent drug entrapment efficiency 
The entrapment efficiency was determined by analyzing the free drug 
content in the supernatant obtained after centrifuging the lipid 
nanoparticulate suspension in a high-speed cooling centrifuge (Remi 
instruments Ltd, India) at 1,7000 rpm for 1 h at 0 °C. The entrapment 
efficiency was calculated as follows and shown in table 1. 
-Eq 2 
Total drug content  
The total amount of drug in the formulation was determined by 
dissolving 1 ml of the formulation in 10 ml of methanol. The amount 
of artemether in each sample was determined using a UV 
spectrophotometer (1700, Shimadzu, Japan) by measuring the 
absorbance at 240 nm λmax. The total drug content was calculated 
using the following equation and given in table 1. 
---Eq 3 
In vitro drug released study 
In vitro release studies were performed using modified Franz 
diffusion cell. Dialysis membrane of 2.4 nm pore size, molecular 
weight cutoff between 12,000–14,000 was used for the study. 
Nanoparticulate formulation (10 mg) was dispersed in 1 ml of 
dissolution medium and placed in the donor compartment and the 
receptor compartment was filled with dialysis medium (25 ml 
phosphate buffer, pH 6.4). At fixed time intervals, 2 ml of the sample 
was withdrawn at different time intervals for 6 h through side tube 
from receiver compartment. Fresh medium was added to maintain a 
constant volume. The artemether content was estimated using 
Shimadzu UV/visible spectrophotometer at wavelength 254 nm and 
the percent drug release at the particular interval was calculated. 
The release study was also carried out for a pure drug for 
comparison with artemether formulation. The percent cumulative 
drug release of optimized solid lipid nanoparticles and pure drug are 
shown in fig. 2. 
In vivo studies 
The in vivo intranasal delivery of optimized formulation was 
assessed on wistar rats (aged 4-5 mo) of either sex weighing 200-
250 g. Animals were procured from the animal house and had free 
access to food and water throughout the duration of the study. The 
study was carried out under the guidelines complied by CPCSEA 
(committee for the purpose of control and supervision of 
experiments on animals), Ministry of Social Justice And 
Empowerment, Government of India, and all the study protocols 
were approved by Institutional Animal Ethical Committee 
(PH/IAEC/VNS/2K12/30 of VNS) of VNS Institute of Pharmacy, 
Bhopal, India. 
The rats were divided into four groups and four rats were selected 
for each group in such a way that same rat can be used for analyzing 
the concentration of artemether in plasma and in cerebrospinal fluid 
on each time interval. While administering the formulation and drug 
suspension; the rats were anaesthetized prior by inhalation of 
diethyl ether. The rats were administered lipid nanoparticles 
intranasally and suspension of artemether orally. The 0.2 ml of 
distilled water dispersed with a weighed quantity of formulations 
(containing an equivalent quantity of dose 1 and dose 2) and pure 
drug (dose 1) was selected for both nasal as well as oral delivery. 
The animal dose of the drug was calculated based on body surface 
area [21]. As the small nano size intranasal formulation was selected 
for to provide fast effect at a low dose, therefore, half and 1/4 
concentration of marketed dose were tried on mice. The first group 
was treated as control and administered with placebo formulation 
intranasally, the second groups was administered intranasally with 
formulation containing dose equivalent to 0.154 mg/kg (Dose 1-
which is ½ of marketed dose) of artemether, third group was also 
intranasally administered with formulation containing 0.077 mg/kg 
(Dose 2-which is ¼ of marketed dose) of artemether which is half 
concentration of the first dose, fourth group was orally administered 
pure drug solution of dose 1 (0.154 mg/kg) of artemether. After 
administration through intranasal and oral route, the artemether 
concentration was analyzed separatelyin the brain and in plasma. 
At different time intervals like 0.25, 0.5, 1, 2, 4, 6, 8 h, the CSF was 
withdrawn from all animals in different group, prior to CSF 
collection, the fur on the neck region of the rat was removed using 
oster clipper and animal was placed in an induction chamber and 
anaesthetized with diethyl ether sprayed on cotton bed placed in 
induction chamber. The position of the animal’s head was 
maintained downward at approximately 45 °. A depressible surface 
with the appearance of a rhomb between the occipital protuberance 
and the spine of atlas becomes visible when cotton embedded in 
ethanol (70%) is rubbed over the surface. A needle connected to 
draw syringe was inserted horizontally and centrally into the 
cisterna magna for the cerebrospinal fluid (CSF) collection without 
making any incision in this region. A change in the resistance along 
this way can be easily felt. A gentle aspiration will make the CSF flow 
through the needle. The colorless CSF sample is slowly drawn into 
the syringe and color of the CSF was closely observed to avoid any 
possible blood contamination. 
After CSF sampling, same animals were used to collect plasma samples 
at different time intervals of 0.25, 0.5, 1, 2, 4, 6, 8 h (fig. 4), for the 
collection of plasma, the anesthetized rat was held in hand with its 
head pointing down. Skin from the eyeball was pulled away so that the 
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eyeball is protruding out of the socket as much as possible. Tip of the 
fine capillary was inserted into the corner of the eye socket 
underneath the eyeball; directing the tip at a 45-degree angle towards 
the middle of the eye socket. The capillary was rotated between 
fingers, the gentle downward pressure was also applied and then 
released until the vein was broken and blood was visualized entering 
the capillary. Blood was collected in a centrifuge tube having 20 µl of 
heparin as an anticoagulant. Plasma was then separated from blood by 
centrifuging in cooling centrifuge at 5700 RPM for 15 min.  
For extraction of artemether from blood, the blood samples were 
mixed with heparin (anticoagulant) in centrifuge tubes and then 
centrifuged at 5700 rpm for 15 min. The plasma samples obtained 
were then mixed with methanol and further centrifuged for 15 min 
the extracted aliquots were then filtered and derivatized for HPLC 
analysis. The same procedure was repeated for CSF samples for 
estimation of the concentration of artemether in cerebrospinal fluid 
by HPLC method [22]. The mobile phase selected for analysis was 
acetonitrile: water (45:55), the flow rate was 0.5 ml/min and the 
detection wavelength was selected at 254 nm.  
RESULTS AND DISCUSSION  
Cerebral malaria comprises the clinical reflections of plasmodium 
falciparum malaria which causes mutations in mental status and 
sometimes, coma. It is an intense disease of the brain, causing ring-like 
lesions in the brain, accompanied by fever. Artemether is a frontline 
drug used in the treatment of malaria. The oral bioavailability of 
artemether is low due to its poor aqueous solubility and degradation 
in acidic pH of the stomach. In present work, we tried to prepare solid 
lipid nanoparticles for intranasal delivery of artemether to provide 
effective treatment in case of cerebral malaria.  
Solid lipid nanoparticles containing artemether were prepared using 
the hot homogenization method. The organic phase with drug and 
lipid was injected into an aqueous phase containing contacting 
surfactant and co-surfactant. The nanosuspension formed was allowed 
to cool at room temperature centrifuged and freeze-dried for further 
use. The prepared nanoparticles were characterized for particle size, 
polydispersity index (PDI), zeta potential, entrapment efficiency, total 
dug content, percent yield and in vitro drug release study.  
Surface morphology of formulation was determined with scanning 
electron microscopy and the photograph is shown in fig. 1. The 
scanning electron microscopy of formulations showed spherical and 
smooth surface of particles.  
 
 
Fig. 1: Scanning electron microscopy of solid lipd nanoparticles
 































F-1 10 0.5 0.5  342.2 0.313 -25.7 54.21 72.10 35.12 
F-2 20 0.5 0.5  358.7 0.489 -18.1 53.29 71.04 42.23 
F-3 30 0.5 0.5  361.8 0.297 -24.6 47.37 78.89 44.21 
F-4 40 0.5 0.5  307.8 0.308 -23.3 59.24 79.23 41.04 
F-5 50 0.5 0.5  259.9 0.448 -17.8 60.10 80.04 39.19 
F-6 60 0.5 0.5  211.6 0.415 -27.2 60.98 80.43 43.21 
F-7 70 0.5 0.5  261.1 0.304 -28.2 54.23 76.35 45.45 
F-8 80 0.5 0.5  245.1 0.316 -20.1 61.09 66.16 39.11 
F-9 90 0.5 0.5  226.3 0.312 -19.0 62.11 79.99 37.96 
F-10 100 0.5 0.5  284.0 0.585 -22.9 59.25 78.10 48.82 
F-11  0.75 0.5  250.0 0.479 -21.3 57.10 70.31 40.80 
F-12  1.0 0.5  219.8 0.723 -27.8 59.99 66.16 32.16 
F-13  0.5 0.5  273.3 0.623 -20.0 60.91 59.70 36.11 
F-14  0.5 0.75  263.7 0.321 -22.3 62.11 69.80 37.16 
F-15  0.5 1.0  258.2 0.432 -23.8 57.10 75.02 41.00 
F-16  0.5 1.0 700 389.9 0.277 -21.0 49.91 78.19 39.99 
F-17  0.5 1.0 800 303.7 0.321 -23.1 46.16 73.46 36.00 
F-18  0.5 1.0 900 289.2 0.551 -24.3 58.19 76.1 42.98 
F-19  0.5 1.0 1000 215.6 0.492 -25.2 59.98 82.64 36.29 
F-20  0.5 1.0 1100 250.4 0.472 -22.0 52.10 69.85 42.45 
F-21  0.5 1.0 1200 282.5 0.522 -24.0 56.29 73.68 49.68 
GMS* = Glyecerylmonosterate **PDI-Polydispersity index 
 
The particle size and polydispersity index were found to be 211.6 nm 
and 0.415 for optimized formulation. The particle size was observed in 
the nano range and found to be significantly affected by an increase in 
the amount of lipid, this may be attributed to the inability of the 
surfactant and co sufcatant solution to stabilize the emulsion at a very 
low concentration (0.5%), however higher (0.7-1%) concentration of 
poloxamer and lecithin was sufficient to stabilize the emulsion even with 
a high lipid load of 80 mg, with a consistent particle size. The zeta 
potential value of optimized formulation was-27 mV (table 1) which is 
attributed to the negative charge of lipid nanoparticles [23]. The 
maximum % yield of the formulation was found to be 49%. 
The maximum entrapment efficiency was 82% (w/w)(table 1). 
Entrapment efficiency was found to be increased with increase in 
the amount of lipid (table 1), which may be due to a greater 
availability of lipid to encapsulate the drug. The increase in 
surfactant and co-surfactant concentration reduces the interfacial 
tension between the lipid and aqueous phase causes the formation 
of a large number of small particles with the large surface area 
which increases the entrapment efficiency of formulations. 
In vitro release studies of artemether contacting solid lipid 
nanoparticles were carried out at 37±1 °C for optimized formulation 
using a phosphate buffer of pH 6.4 as dissolution medium. The 
cumulative percent release profile of artemether is given in fig. 2. The 
optimized formulation showed 98.07±1.521% drug release form 
nanoformulation. The release of of artemether was much higher than a 
pure drug, which could be due to smaller particle size and sustain 
release properties of solid lipid nanoparticles. The result showed that 
the optimized formulation gives the most consistent drug release 
pattern, which showed that formulation is able to release artemether 
for long period of time which would be helpful for the eradication of all 
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parasite in the brain and in blood in case of more complicated malaria where the conventional formulation is not effective. 
  
 
Fig. 2: Release profile of pure artemether and artemether from solid lipid nanoparticles n=3±SD, SD= standard deviation 
 
The prepared nanoparticulate formulation was finally assessed for 
in vivo performance on wistar rats. The objective of in vivo study was 
to evaluate different pharmacokinetic parameters of intranasal 
nanoformulations and compare the efficacy with an oral solution of 
artemether. The drug-containing formulations were administered 
intranasally and the same dose of the pure drug was given by oral 
route to observe the concentration difference in the brain after 
administration of the same dose through a different route. The 
formulation containing half concentration of dose was also 
evaluated for efficacy along with optimized formulation. 
In vivo study were conducted on wistar rats after administration of 
artemether containing solid lipid nanoparticles intranasally and 
compared with plain artemether suspension administered orally. 
After administration of formulation through both intranasal as well 
oral routes, the concentration of artemether was analyzed in 
cerebrospinal fluid and in plasma. After collection of plasma and 
cerebrospinal fluid (CSF) samples at different time intervals, the 
samples were derivatized for HPLC analysis. Derivatization involved 
an acid decomposition with hydrochloric acid to produce a UV–
absorbing product, and α, β-unsaturated decalone [8-methyl-5-(2-
propanalyl) decalin-4ene-3one], which gave absorbance at 
wavelength 254 nm. 
The results showed that plasma T1/2 was found to be 4.95 h when 
nanoparticles administered intranasally, while it was found to be 2.4 
h when artemether suspension administered orally which is 
attributed to the capability of the intranasal formulation to sustain 
the release and maintain the effective concentration of artemether in 
cerebrospinal fluid. The higher concentration (644.6 ng/ml) was 
achieved in brain after intranasal administration of artemether 
containing formulation in 1 h than that achieved (69.20 ng/ml) in 4 
h after same dose of oral administration of artemether suspension 
which is attributed to nanosize of formulation that may enter the 
brain directly when administered through intranasal route which 
will not only provide fast effective action, it would also release the 
drug in brain in a sustained manner and would be able to remove 
malaria parasite from brain. 
  
Table 2: Details of formulations administered through a different route and analysis of drug in the brain (cerebrospinal fluid) and plasma 
Group(s) Group Route  Concentration analysised in Animal used 
Group-I 
(Control) 
Placebo SLN formulation IN Brain 4 
Placebo SLN formulation IN Blood - 
Group-II 
 
SLN formulation (dose 0.154 mg/kg) IN Brain 4 
SLN formulation (dose 0.154 mg/kg) IN Blood - 
Group-III 
 
SLN formulation(dose 0.077 mg/kg) IN Brain 4 
SLN formulation (dose 0.077 mg/kg) IN Blood - 
Group-IV 
 
Artemether drug solution(dose 0.154 mg/kg) Oral Brain 4 
Artemether drugSolution(dose 0.154 mg/kg) Oral Blood - 
SLN= solid lipid nanoparticles, IN = intranasal  
 
Table 3: Pharmacokinetic parameters of artemether containing solid lipid nanoparticles and pure drug solution after intranasal and oral 
administration (n=4±SD, SD= standard deviation) 
Pharmacokinetic parameters Calculated values for blood and CSF samples 
CSF Plasma 
Oral IN Oral IN 
Dose 1 Dose 2 Dose 1 Dose 2 
K (ng/hr) 0.287 0.14 0.19 0.46 0.16 0.24 
t1/2 (h) 2.4 4.95 3.6 1.5 4.3 3.01 
Cmax (ng/ml) 69.20 644.60*** 247.04 124.05 271.75 104.85 
Tmax (h) 4 1 1 1 2 2 
Vd (l/kg) 10.70 2.7 5.2 4.7 5.39 8.3 
Cl (l. hr/kg) 2.1 0.37 0.98 3.07 0.86 1.9 
[AUC]0∞(nghr/ml) 700.7 3970.54 1540.43 500.9 1783.0 770.6 
Dose (mg/kg) 0.154 0.154 0.077 0.154 0.154 0.077 
IN= intra nasal, CSF = cerebrospinal fluid, Cmax =maximum serum concentration, t1/2 = biological half-life, Tmax =time for peak plasma concentration, 
Vd = Volume of distribution, AUC = area under the curve, Cl = body clearance, K = elimination rate constant, ***= P<0.001 
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The pharmacokinetic parameters like maximum serum 
concentration (Cmax), time for peak plasma concentration (Tmax), 
biological half-life (T1/2), area under curve (AUC), body clearance 
(CL) and Volume of distribution (Vd) were calculated from the 
individual cerebroipinal fluid (CSF) and plasma concentration-time 
profile experiments after intranasal and oral administration of 
formulations as shown in table 3. The results of optimized 
formulation showed the value of half-life (T1/2)-4.95 h, maximum 
serum concentration (Cmax) was 644.60ng/ml, time for 
peak plasma concentration (Tmax) was 1 h, Volume of distribution Vd 
was 2.7l/kg, Cl-0.37 lhr/kg and area under curve [AUC]0∞ was 
3970.5nghr/ml for formulation. 
When the pharmacokinetic parameters for the formulations of the 
same dose were compared the lower Tmax value for the brain (1 hr) 
was observed as compared to blood (2 h) which is attributed to the 
preferential nose to brain transport following intranasal 
administration. When the peak plasma concentration (Cmax) and area 
under curve (AUC) of brain concentrations of artemther solid lipid 
nanoparticles (SLN) formulation (intranasal) and artemether 
suspension (oral) were compared, the peak plasma concentration 
(Cmax) 644.60 ng/ml and area under curve (AUC) 3970.5nghr/ml of 
artemether SLN formulation were found to be significantly higher; 
this could be because of the direct transport of drug through 
olfactory route by bypassing BBB. 
 
 
Fig. 3: Concentration of the drug in cerebrospinal fluid after intranasal and oral administration of formulations with different dose. 
n=4±SD, SD= standard deviation, SNL= solid lipid nanoparticles) 
 
 
Fig. 4: Concentration of drug in plasma after intranasal and oral administration of formulations with different dose. n=4±SD, SD= 
standard deviation, SNL=Solid lipid nanoparticles) 
 
The results also revealed that when solid lipid nanoparticles (SLN) 
formulation of artemether containing 0.077 mg dose of drug was 
given through intranasal route showed higher concentration in CSF 
than artemether suspension (0.154 mg of dose) given orally, which 
again confirmed that through intranasal route artemther may 
directly reach the brain which reveals that formulations are effective 
at low dose and may be more effective than available marketed 
formulation. Data from in vivo experiments were analyzed 
statistically by one-way analysis of variance (ANOVA) with Tukey-
Kramer multiple comparison post-test methods. The software used 
was GraphPad InStat. The statistically difference between groups 
was defined as p<0.001. The overall p-value was extremely 
significant (p<0.0001).  
CONCLUSION 
The result of the study indicates that solid lipid nanoparticles could 
be a potential carrier for artemether delivery to the brain in the 
treatment of cerebral malaria. In vivo study proves that 
bioavailability of artemether from solid lipid nanoparticles 
formulation was far better than oral suspension of artemether. The 
study concluded that formulation with a half dose of intranasal 
preparation exhibit more concentration in brain than that of 
concentration achieved by the oral route. The results of the present 
study indicated that delivering artemether intranasally for targeting 
the CNS would be a promising approach for the treatment of 
cerebral malaria.  
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